

<b>Product Name</b>	: JGB1741
<b>Synonyms</b>	: ILS-JGB-1741
<b>Cat No.</b>	: M27505
<b>CAS Number</b>	: 1256375-38-8
<b>Molecular Formula</b>	: C <sub>27</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub> S
<b>Formula Weight</b>	: 440.6
<b>Chemical Name</b>	: —
<b>Description</b>	<p>JGB1741 is a potent and selective inhibitor of SIRT1 with an IC<sub>50</sub> of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer. (In Vitro): JGB1741 (1-10000 nM) inhibits the cell proliferation of K562, HepG2 and MDA-MB 231 cell lines. JGB1741 (0.01-1 μM) induces apoptosis of MDA-MB 231 and shows a cell cycle arrest at G1 phase with more cells entering into sub G0/G1 phase. JGB1741 (0.01-1 μM) increases the global acetylation of H3K9, acetylated p53K382 levels and p53 expression.</p>
<b>Pathway</b>	: Chromatin/Epigenetic
<b>Target</b>	: Sirtuin
<b>Receptor</b>	: Aurora B
<b>Solubility</b>	: —
<b>SMILES</b>	: <chem>C(NCC1=CC=CC=C1)(=O)C=CC3=C(SC2/N=C/C=CC5=C(C=CC4O)C=CC=C5)CCCC3</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1.1. Naga Rajiv Lakkaniga, et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. Eur J Med Chem. 2020 Jul 12;203:112589.